CARsgen Therapeutics Holdings Limited

SZSC:2171 Stock Report

Market Cap: HK$3.9b

CARsgen Therapeutics Holdings Past Earnings Performance

Past criteria checks 0/6

CARsgen Therapeutics Holdings has been growing earnings at an average annual rate of 28.9%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 64.8% per year.

Key information

28.9%

Earnings growth rate

47.5%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate-64.8%
Return on equity-46.4%
Net Margin-10,960.3%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CARsgen Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSC:2171 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 246-695159581
31 Mar 243-721146620
31 Dec 230-748133660
30 Sep 230-834135673
30 Jun 230-920136686
31 Mar 230-906136683
31 Dec 220-892137679
30 Sep 2213-810131660
30 Jun 2226-727126641
31 Mar 2226-2,736126571
31 Dec 2126-4,744127501
30 Sep 2113-4,831124416
30 Jun 210-4,917121332
31 Mar 210-2,99199306
31 Dec 200-1,06478281

Quality Earnings: 2171 is currently unprofitable.

Growing Profit Margin: 2171 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2171 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.9% per year.

Accelerating Growth: Unable to compare 2171's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2171 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).


Return on Equity

High ROE: 2171 has a negative Return on Equity (-46.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies